ethyl 1-methoxycarbonyl-4-piperidinecarboxylate | 439944-43-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: ethyl 1-methoxycarbonyl-4-piperidinecarboxylate
• 英文别名: 1-Carbomethoxy-4-carboethoxy-piperidin；4-Ethyl 1-methyl piperidine-1,4-dicarboxylate；4-O-ethyl 1-O-methyl piperidine-1,4-dicarboxylate
• CAS: 439944-43-1
• 化学式: C₁₀H₁₇NO₄
• mdl: MFCD09836651
• 分子量: 215.249
• InChiKey: TWULIESUCDGNSQ-UHFFFAOYSA-N

物化性质

• 保留指数：
  1599

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  55.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 1-methoxycarbonyl-4-piperidinecarboxylate 在 sodium hydroxide 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 5.5h， 生成 4-甲基-4-哌啶羧酸(9ci)
  参考文献：
  名称：

  Novel Class of Potent 4-Arylalkyl Substituted 3-Isoxazolol GABA_A Antagonists:  Synthesis, Pharmacology, and Molecular Modeling

  摘要：

  A number of analogues of the low-efficacy partial GABA(A) agonist 5-(4-piperidyl)-3-isoxazolol (4-PIOL, 5), in which the 4-position of the 3-isoxazolol ring was substituted by different groups, were synthesized and tested as GABA(A) receptor ligands. Substituents of different size and structural flexibility such as alkyl, phenylalkyl, diphenylalkyl, and naphthylalkyl were explored. Pharmacological characterization of the synthesized compounds was carried out using receptor binding assays and by electrophysiological experiments using whole-cell patch-clamp techniques. Whereas none of these compounds significantly affected GABA(B) receptor sites or GABA uptake, they did show affinity for the GABA(A) receptor site. While alkyl or benzyl substitution, compounds 7a-h, provided receptor affinities comparable with that of 5 (K-i = 9.1 muM), diphenylalkyl and naphthylalkyl substitution, as in compounds 7m-t, resulted in a dramatic increase in affinity relative to 5. The 3,3-diphenylpropyl and the 2-naphthylmethyl analogues, compounds 7s and 7m, respectively, showed the highest affinities of the series (K-i = 0.074 muM and K-i = 0.049 muM). In whole-cell patch-clamp recordings from cultured cerebral cortical neurons, all of the tested compounds were able to inhibit the effect of the specific GABA(A) agonist isoguvacine (1), compounds 7m and 7s showing antagonist potency (IC50 = 0.37 muM and IC50 = 0.02 muM) comparable with or markedly higher than that of the standard GABA(A) antagonist 4 (IC50 = 0.24 muM). Highly potent convulsant activity was demonstrated in mice with compounds 7m (ED50 = 0.024 mumol/kg) and 7s (ED50 = 0.21 mumol/kg) after intracerebroventricular administration, whereas no effects were found after subcutaneous administration. According to a previously proposed pharmacophore model for GABA(A) receptor agonists, a receptor cavity in the vicinity of the 4-position of the 3-isoxazolol ring in 4-PIOL exists. A molecular modeling study, based on compounds 7o,m,l,q,s, was performed to explore the dimensions and other properties of the receptor cavity. This study demonstrates the importance of the arylalkyl substituents in 7m and 7s and the considerable dimensions of this proposed receptor cavity.

  DOI：

  10.1021/jm020027o
• 作为产物：
  描述：

  哌啶-4-甲酸乙酯 、 氯甲酸甲酯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 ethyl 1-methoxycarbonyl-4-piperidinecarboxylate
  参考文献：
  名称：

  氨基甲酸酯介导的环状氨基甲酸酯的电化学功能基团耐受的Shono型氧化。

  摘要：

  已经开发出一种电化学方法，用于通过使用双环氨基己基作为介质和以水作为亲核试剂来对环状氨基甲酸酯进行α-加氧。介导的电化学过程使底物氧合作用的电位比氨基甲酸酯底物的氧化还原电位低约1V。此功能可实现常规的Shono氧化无法实现的官能团相容性，而传统的Shono氧化则通过直接电化学底物氧化来进行。该反应也代表了未活化的环状氨基甲酸酯与氧铵铵氧化剂的首次α-官能化。

  DOI：

  10.1002/anie.201803539

文献信息

• O-substituted hydroxyaryl derivatives
  申请人：Muto Susumu

  公开号：US20060094718A1

  公开（公告）日：2006-05-04

  A medicament having inhibitory activity against NF-κB activation which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in a main chain is 2 to 5 (said connecting group may be substituted), “A” represents an acyl group which may be substituted, (provided that unsubstituted acetyl group and unsubstituted acryloyl group are excluded,) or a C 1 to C 6 alkyl group which may be substituted, or A may bind to connecting group X to form a cyclic structure which may be substituted, “E” represents an aryl group which may be substituted or a heteroaryl group which may be substituted, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above.

  一种药物具有抑制NF-κB激活活性，其包括以下通式(I)所表示的化合物或其药学上可接受的盐、水合物或溶剂化物作为活性成分，其中X表示主链中原子数为2至5的连接基（该连接基可以被取代），A表示可以被取代的酰基（不包括未取代的乙酰基和未取代的丙烯酰基）或者可以被取代的C1到C6烷基，或者A可以与连接基X结合形成可以被取代的环状结构，E表示可以被取代的芳基或者可以被取代的杂环基，环Z表示可以具有一个或多个取代基的芳基（除了由式—O-A所表示的基团外，A具有与上述定义相同的含义，由式—X-E所表示的基团，X和E具有与上述定义相同的含义）或者可以具有一个或多个取代基的杂环基（除了由式—O-A所表示的基团外，A具有与上述定义相同的含义，由式—X-E所表示的基团，X和E具有与上述定义相同的含义）。
• CASPASE INHIBITOR AND PHARMACEUTICAL COMPOSITION, USE AND THERAPEUTIC METHOD THEREOF
  申请人：Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

  公开号：EP3456711A1

  公开（公告）日：2019-03-20

  Disclosed are a class of compounds as a caspase inhibitor, and in particular the compound as shown in formula (I) or a pharmaceutically acceptable salt thereof, and the use of the compound in treating caspase-related diseases.

  公开了一类作为 Caspase 抑制剂的化合物，特别是如式（I）所示的化合物或其药学上可接受的盐，以及该化合物在治疗 Caspase 相关疾病中的用途。
• Caspase inhibitor and pharmaceutical composition, use and therapeutic method thereof
  申请人：Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

  公开号：US10981860B2

  公开（公告）日：2021-04-20

  Disclosed are a class of compounds as a caspase inhibitor, and in particular the compound as shown in formula (I) or a pharmaceutically acceptable salt thereof, and the use of the compound in treating caspase-related diseases.

  公开了一类作为 Caspase 抑制剂的化合物，特别是如式（I）所示的化合物或其药学上可接受的盐，以及该化合物在治疗 Caspase 相关疾病中的用途。
• EP3456711
  申请人：——

  公开号：——

  公开（公告）日：——
• O-SUBSTITUTED HYDROXYARYL DERIVATIVES
  申请人：Institute of Medicinal Molecular Design, Inc.

  公开号：EP1512397B1

  公开（公告）日：2014-10-08